Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sunshine Biopharma Inc's HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic At High Concentrations


Tuesday, 9 Apr 2013 08:00am EDT 

Sunshine Biopharma Inc announced that it has completed several new IND-Enabling studies, including one in which the cytotoxic activity of Adva-27a, the Company's flagship oncology drug candidate, was measured in the HMEC cell line. HMEC are normal (non-cancerous) human mammary epithelial cells isolated from reduction mammoplasty tissue. The HMEC cell line is the standard cell line used for investigating the molecular and biochemical basis for in vitro toxicity of various drug candidates. The data of the present HMEC studies indicated that concentrations of up to 24 micromolar of Adva-27a did not appreciably inhibit the normal growth process of these cells. These data indicate that Adva-27a will likely not be toxic or damaging to healthy tissue, a key component for planned clinical trials, as toxicity is what stops drugs in early development, said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. 

Company Quote

0.0799
-0.0051 -6.00%
3:45pm EDT